

Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market – Analysis By Drug Type, Distribution Channel, By Region, and By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)

https://marketpublishers.com/r/G5DB9AF55F49EN.html

Date: August 2021

Pages: 200

Price: US\$ 2,400.00 (Single User License)

ID: G5DB9AF55F49EN

Abstracts

Executive Summary

Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market was valued at USD 5.5 billion in the year 2020. The key factors driving growth in the global Gastroesophageal Reflux Disease Therapeutics market is increased public awareness of the disease and its symptoms. The growing incidence of heartburn is likely to create new economic prospects for acid-reducing medications and proton pump inhibitors, resulting in the rapid growth of GERD therapeutics market. Other potential includes an increase in risk of GERD disease in emerging nations and technological advancements that allow for speedier diagnosis of the condition.

Protein pump inhibitors (PPIs) are the front line therapy for the treatment of GERD. The market of GERD is very large in the US and in European countries and mostly catered by PPIs. Although PPIs control the major share of the market but with PPIs providing limited relief and the treatment generally relapsing within 6-months, the market for acid blockers like Vonoprazan looks very lucrative with physicians also supports its efficacy in GERD management. Also, the US GERD market is highly price sensitive because of the availability of generics in the market and hence any drug, even with higher efficiency, will have to price rationally to gain share of the market.

The increasing prevalence of gastroesophageal reflux disease is correlated with the increasing prevalence of obesity in many countries and presence of other poor diet and



lifestyle factors. Several environmental factors and the prominent lifestyle evolution to sedentary habits such as a high dietary fat intake, shorter dinner-to-bed time, and frequent smoking and alcohol consumption have been proven as the high risk factors associated with the prevalence of gastroesophageal reflux diseases.

North America region dominates the Gastroesophageal Reflux Disease Therapeutics Market. High incidence of obesity-driven GERD and innovation in drugs in GERD treatments are factors that have helped cement the potential of the North America GERD therapeutics market. Moreover, high per capita expenditure on healthcare coupled with extended life expectancy of consumers in the region has been creating a sustainable demand for the superior treatment for the GERD in North America.

Scope of the Report

The report presents the analysis of Gastroesophageal Reflux Disease (GERD) Therapeutics Market for the historical period of 2016-2020 and the forecast period of 2021-2026.

The report analyses Gastroesophageal Reflux Disease Therapeutics Market By Value.

The report analyses Gastroesophageal Reflux Disease Therapeutics Market By Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors)

The report further assesses the Gastroesophageal Reflux Disease Therapeutics Market By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)

The Global Gastroesophageal Reflux Disease Therapeutics Market has been analysed By Region (North America, Europe and Asia Pacific) and By Country (United States, Canada, Germany, France, Italy, United Kingdom, Spain, China, Japan, India)

The key insights of the report have been presented through the frameworks of Pipeline Development. Also, the attractiveness of the market has been presented By Region, By Drug Type and By Distribution Channel. Additionally, trends, drivers and challenges of the industry has been analysed in the report.

The companies analysed in the report include Phathom Pharmaceuticals, Eisai,



Takeda Pharmaceutical Company, Daewoong Pharmaceutical, Ironwood Pharmaceuticals, Johnson & Johnson, EndoGastric Solutions, CHEPLAPHARM Arzneimittel, Merck & Co. and Olympus Corporation.

Key Target Audience

Gastroesophageal Reflux Disease Drug Manufacturers

Pharmaceutical Industry

Biotechnology Companies

Pharmacies, and Retailers

Government and Research Organisations

Consulting and Advisory Firms

Investment Banks and Equity Firms



Contents

1. REPORT SCOPE AND METHODOLOGY

- 1.1 Scope of the Report
- 1.2 Research Methodology
- 1.3 Executive Summary

2. STRATEGIC RECOMMENDATIONS

3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE (GERD) THERAPEUTICS MARKET PRODUCT OVERVIEW

4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: AN ANALYSIS

- 4.1 Market Size, By Value, Year 2016-2026
- 4.2 COVID-19 Impact on Gastroesophageal Reflux Disease Therapeutics Market

5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SEGMENTATION BY DRUG TYPE

- 5.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Drug Type
- 5.2 Antacids Market Size and Forecast (2016-2026)
- 5.3 H2 Receptor Blockers Market Size and Forecast (2016-2026)
- 5.4 Proton Pump Inhibitors Market Size and Forecast (2016-2026)

6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SEGMENTATION BY DISTRIBUTION CHANNEL

- 6.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Distribution Channel
- 6.2 Hospital Pharmacies Market Size and Forecast (2016-2026)
- 6.3 Retail Pharmacies Market Size and Forecast (2016-2026)
- 6.4 Online Pharmacies Market Size and Forecast (2016-2026)

7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: REGIONAL ANALYSIS



7.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Region

8. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: AN ANALYSIS (2016-2026)

- 8.1 North America Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 8.2 North America Gastroesophageal Reflux Disease Therapeutics Market Prominent Companies
- 8.3 Market Segmentation By Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors)
- 8.4 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
- 8.5 North America Gastroesophageal Reflux Disease Therapeutics Market: Country Analysis
- 8.6 Market Opportunity Chart of North America Gastroesophageal Reflux Disease Therapeutics Market By Country, By Value (Year-2026)
- 8.7 Competitive Scenario of North America- By Country
- 8.8 United States Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 8.9 Prominent Companies in Gastroesophageal Reflux Disease Therapeutics Market
- 8.10 United States Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
- 8.11 Canada Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 8.12 Canada Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.

9. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: AN ANALYSIS (2016-2026)

- 9.1 Europe Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 9.2 Europe Gastroesophageal Reflux Disease Therapeutics Market Prominent Companies
- 9.3 Market Segmentation By Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors)



- 9.4 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
- 9.5 Europe Gastroesophageal Reflux Disease Therapeutics Market: Country Analysis
- 9.6 Market Opportunity Chart of Europe Gastroesophageal Reflux Disease Therapeutics Market By Country, By Value (Year-2026)
- 9.7 Competitive Scenario of Europe- By Country
- 9.8 Germany Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 9.9 Prominent Companies in Gastroesophageal Reflux Disease Therapeutics Market
- 9.10 Germany Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
- 9.11 France Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 9.12 France Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
- 9.13 United Kingdom Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 9.14 Prominent Companies in Gastroesophageal Reflux Disease Therapeutics Market
- 9.15 United Kingdom Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
- 9.16 Italy Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 9.17 Italy Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
- 9.18 Spain Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 9.19 Spain Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.

10. ASIA PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET: AN ANALYSIS (2016-2026)

- 10.1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 10.2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Prominent Companies
- 10.3 Market Segmentation By Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors)
- 10.4 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail



Pharmacies and Online Pharmacies)

- 10.5 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market: Country Analysis
- 10.6 Market Opportunity Chart of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market By Country, By Value (Year-2026)
- 10.7 Competitive Scenario of Asia Pacific- By Country
- 10.8 China Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 10.9 China Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
- 10.10 Japan Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 10.11 Prominent Companies in Gastroesophageal Reflux Disease Therapeutics Market
- 10.12 Japan Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
- 10.13 India Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
- 10.14 India Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.

11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET DYNAMICS

- 11.1 Global Gastroesophageal Reflux Disease Therapeutics Market Drivers
- 11.2 Global Gastroesophageal Reflux Disease Therapeutics Market Restraints
- 11.3 Global Gastroesophageal Reflux Disease Therapeutics Market Trends

12. MARKET ATTRACTIVENESS

- 12.1 Market Attractiveness Chart of Global Gastroesophageal Reflux Disease Therapeutics Market By Drug Type, By Value (Year-2026)
- 12.2 Market Attractiveness Chart of Global Gastroesophageal Reflux Disease Therapeutics Market By Distribution Channel, By Value (Year-2026)
- 12.3 Market Attractiveness Chart of Global Gastroesophageal Reflux Disease Therapeutics Market By Region, By Value (Year-2026)

13. COMPETITIVE LANDSCAPE

13.1 Market Share Analysis



13.2 Gastroesophageal Reflux Disease Therapeutics Pipeline

14. COMPANY PROFILES (BUSINESS DESCRIPTION, FINANCIAL ANALYSIS, BUSINESS STRATEGY)

- 14.1 Phathom Pharmaceuticals
- 14.2 Eisai
- 14.3 Takeda Pharmaceutical Company
- 14.4 Daewoong Pharmaceutical
- 14.5 Ironwood Pharmaceuticals
- 14.6 Johnson & Johnson
- 14.7 EndoGastric Solutions
- 14.8 CHEPLAPHARM Arzneimittel
- 14.9 Merck & Co.
- 14.10 Olympus Corporation



Tables & Figures

TABLES AND FIGURES

Figure 1: Global Gastroesophageal Reflux Disease Therapeutics Market Size, By

Value, 2016-2026 (USD Million)

Figure 2: Projected global population (In Billions)

Figure 3: Population ages 65 and above, By Select Region, 2016-2020 (% of total)

Figure 4: Projected global population aged 60 years & above (In Billions)

Figure 5: Prevalence of Gastroesophageal Reflux Disease, By Region, 2017 (In %)

Figure 6: Prevalence of GERD and Estimated Population in United States and EU

Figure 7: Global Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type

Market Share, 2020 & 2026

Figure 8: Global Gastroesophageal Reflux Disease Therapeutics Market- By Antacids,

By Value (USD Million), 2016-2026

Figure 9: Global Gastroesophageal Reflux Disease Therapeutics Market- By H2

Receptor Blockers, By Value (USD Million), 2016-2026

Figure 10: Global Gastroesophageal Reflux Disease Therapeutics Market- By Proton

Pump Inhibitors, By Value (USD Million), 2016-2026

Figure 11: Global Gastroesophageal Reflux Disease Therapeutics Market- By

Distribution Channel Market Share, 2020 & 2026

Figure 12: Global Gastroesophageal Reflux Disease Therapeutics Market- By Hospital

Pharmacies, By Value (USD Million), 2016-2026

Figure 13: Global Gastroesophageal Reflux Disease Therapeutics Market- By Retail

Pharmacies, By Value (USD Million), 2016-2026

Figure 14: Global Gastroesophageal Reflux Disease Therapeutics Market- By Online

Pharmacies, By Value (USD Million), 2016-2026

Figure 15: Global Gastroesophageal Reflux Disease Therapeutics Market- By Region

Market Share, 2020 & 2026

Figure 16: North America Gastroesophageal Reflux Disease Therapeutics Market Size,

By Value, 2016-2026 (USD Million)

Figure 17: North America Healthcare Cost Per Capita, 2018 (USD)

Figure 18: North America Population above 65 year, 2015, 2030F, & 2050F (In Millions)

Figure 19: North America Gastroesophageal Reflux Disease Therapeutics Market-By

Drug Type, By Value (USD Million), 2016-2026

Figure 20: North America Gastroesophageal Reflux Disease Therapeutics Market- By

Distribution Channel, By Value (USD Million), 2016-2026

Figure 21: Market Opportunity Chart of North America Gastroesophageal Reflux

Disease Therapeutics Market- By Country, By Value (Year-2026)

Figure 22: North America Gastroesophageal Reflux Disease Therapeutics Market- By



Country Market Share, 2020 & 2026

Figure 23: United States Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)

Figure 24: United States Per Capita Expenditure on Healthcare, 2012-2018 (In USD)

Figure 25: United States healthcare expenditure as percentage of GDP

Figure 26: United States Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 27: United States Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 28: Canada Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)

Figure 29: Canada Gastroesophageal Reflux Disease Facts

Figure 30: Canada Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 31: Canada Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 32: Europe Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)

Figure 33: Population ages 65 and above (% of total population) - European Union

Figure 34: Gross domestic expenditure on R&D (GERD) as a % of GDP in selected European countries

Figure 35: Per Capita Health Expenditure, By Select Country, 2018 (USD)

Figure 36: Breakdown of Total Health Expenditure in Europe, 2018 (%)

Figure 37: Europe Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 38: Europe Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 39: Market Opportunity Chart of Europe Gastroesophageal Reflux Disease Therapeutics Market- By Country, By Value (Year-2026)

Figure 40: Europe Gastroesophageal Reflux Disease Therapeutics Market, By Country, 2020, 2026

Figure 41: Germany Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)

Figure 42: Germany Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 43: Germany Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 44: France Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)



Figure 45: France Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 46: France Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 47: United Kingdom Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)

Figure 48: United Kingdom Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 49: United Kingdom Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 50: Italy Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)

Figure 51: Share of individuals affected by gastroesophageal reflux disease in Italy in 2009 and 2018

Figure 52: Share of individuals affected by gastroesophageal reflux disease in Italy as of 2018, by gender

Figure 53: Italy Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 54: Italy Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 55: Spain Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)

Figure 56: Spain Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 57: Spain Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 58: Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)

Figure 59: Population ages 65 and above, APAC Region, By Select Countries, 2017 (% of total)

Figure 60: Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)

Figure 61: Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 62: Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 63: Market Opportunity Chart of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market- By Country, By Value (Year-2026)

Figure 64: Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, By



Country, 2020, 2026

Figure 65: China Gastroesophageal Reflux Disease Therapeutics Market Size, By

Value, 2016-2026 (USD Million)

Figure 66: Share of overweight population in China as of 2019, by gender

Figure 67: Share of adult population who smoke in China from 2014 to 2018, by gender

Figure 68: China Gastroesophageal Reflux Disease Therapeutics Market- By Drug

Type, By Value (USD Million), 2016-2026

Figure 69: China Gastroesophageal Reflux Disease Therapeutics Market- By

Distribution Channel, By Value (USD Million), 2016-2026

Figure 70: Japan Gastroesophageal Reflux Disease Therapeutics Market Size, By

Value, 2016-2026 (USD Million)

Figure 71: Vonoprazan Sales in Japan, in USD Million from 2015 - 2020

Figure 72: Japan Healthcare Expenditure Outlook (%)

Figure 73: Japan Median Age of population from 2010 to 2050 (in years)

Figure 74: Top Pharma Companies In Japan, based on sales in 2019, USD Billions

Figure 75: Domestic private health expenditure (% of current health expenditure) -

Japan

Figure 76: Japan Gastroesophageal Reflux Disease Therapeutics Market- By Drug

Type, By Value (USD Million), 2016-2026

Figure 77: Japan Gastroesophageal Reflux Disease Therapeutics Market- By

Distribution Channel, By Value (USD Million), 2016-2026

Figure 78: India Gastroesophageal Reflux Disease Therapeutics Market Size, By Value,

2016-2026 (USD Million)

Figure 79: India Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type,

By Value (USD Million), 2016-2026

Figure 80: India Gastroesophageal Reflux Disease Therapeutics Market- By Distribution

Channel, By Value (USD Million), 2016-2026

Figure 81: Market Attractiveness Chart of Global Gastroesophageal Reflux Disease

Therapeutics Market- By Drug Type (Year-2026)

Figure 82: Market Attractiveness Chart of Global Gastroesophageal Reflux Disease

Therapeutics Market- By Distribution Channel (Year-2026)

Figure 83: Market Attractiveness Chart of Global Gastroesophageal Reflux Disease

Therapeutics Market- By Region (Year-2026)

Figure 84: Global Gastroesophageal Reflux Disease Therapeutics company market

share (%), 2020

Figure 85: Eisai Annual Sales Revenue (USD Million), 2016-2020

Figure 86: Eisai Annual Net Income/Loss (USD Million), 2016-2020

Figure 87: Eisai sales Revenues, By Business Segment (%), FY2020

Figure 88: Eisai sales Revenue, By Geographical Segment (%), FY2020



Figure 89: Takeda Pharmaceutical Company Annual Sales Revenue (USD Million), 2016-2020

Figure 90: Takeda Pharmaceutical Company Annual Net Income/Loss (USD Million), 2016-2020

Figure 91: Takeda Pharmaceutical Company sales Revenues, By Business Segment (%), FY2020

Figure 92: Takeda Pharmaceutical Company sales Revenue, By Geographical Segment (%), FY2020

Figure 93: Daewoong Pharmaceutical Annual Sales Revenue (USD Million), 2016-2020

Figure 94: Daewoong Pharmaceutical Annual Net Income/Loss (USD Million), 2016-2020

Figure 95: Ironwood Pharmaceuticals Annual Sales Revenue (USD Million), 2016-2020

Figure 96: Ironwood Pharmaceuticals Annual Net Income/Loss (USD Million),

2016-2020

Figure 97: Ironwood Pharmaceuticals sales Revenues, By Geography Segment (%), FY2019

Figure 98: Ironwood Pharmaceuticals sales Revenue, By Geographical Segment (%), FY2020

Figure 99: Johnson & Johnson Annual Sales Revenue (USD Million), 2016-2020

Figure 100: Johnson & Johnson Annual Net Income/Loss (USD Million), 2016-2020

Figure 101: Johnson & Johnson sales Revenues, By Business Segment (%), FY2020

Figure 102: Johnson & Johnson sales Revenue, By Geographical Segment (%), FY2020

Figure 103: Merck & Co. Annual Sales Revenue (USD Million), 2016-2020

Figure 104: Merck & Co. Annual Net Income/Loss (USD Million), 2016-2020

Figure 105: Merck & Co. sales Revenues, By Business Segment (%), FY2020

Figure 106: Merck & Co. sales Revenue, By Geographical Segment (%), FY2020

Figure 107: Olympus Corporation Annual Sales Revenue (USD Million), 2017-2020

Figure 108: Olympus Corporation Annual Net Income/Loss (USD Million), 2017-2020

Table A: Health expenditures in Germany as share of GDP and in millions of Euro

Table B: % OF ADULT POPULATION WITH GASTROINTESTINAL CONDITIONS IN FRANCE

Table C: % OF ADULT POPULATION WITH MEDICATION USAGE FOR GASTROINTESTINAL CONDITIONS IN FRANCE

Table D: Factor for Gastrointestinal Conditions in United Kingdom based on the age group

Table E: % OF ADULT POPULATION WITH GASTROINTESTINAL CONDITIONS IN SPAIN

Table F: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific



Region, 2017 (score out of 10)

Table G: Upcoming potential pipeline catalysts

Table H: Takecab (Takeda) the first-line therapy for GERD



I would like to order

Product name: Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market - Analysis By

Drug Type, Distribution Channel, By Region, and By Country (2021 Edition): Market

Insights and Forecast with Impact of COVID-19 (2021-2026)

Product link: https://marketpublishers.com/r/G5DB9AF55F49EN.html

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G5DB9AF55F49EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970